패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
Exploration Score · catalog ranks
Rule-based Catalog Exploration Score for pharmacophore cores and drug/derivative nodes. Not an efficacy prediction.
StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.
Core structure exploration tiers
Rule-based Catalog Exploration Score from SMILES similarity, approved/clinical tags, family network size, and SAR metadata. It does not predict efficacy, safety, or development success.
StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.
How similarity is calculated · How clustering works · How exploration priority is scored
치료 영역 · 계열
HighHigh exploration priority9
Highest Exploration Score percentile in this pool (X-S bin)
| High exploration priority | 2D | Structure | Class | Exploration Score | Factors |
|---|---|---|---|---|---|
| High | 4-Anilinoquinazoline EGFR core EGFR tyrosine kinase inhibitor series · Scaffold | EGFR TKI | 100 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| High | Aminobenzothiazole core ALS neuroprotectant series · Scaffold | ALS | 100 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| High | Aryloxy-propylamine core SSRI / SNRI antidepressant series · Scaffold | Antidepressant · SSRI/SNRI | 100 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| High | BTK pyrazolo-pyrimidine core BTK inhibitor chemical series · Scaffold | BTK inhibitor | 100 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| High | Catecholamine / amino-acid core Parkinson dopaminergic / MAO-B series · Scaffold | Parkinson | 100 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| High | Daraxonrasib core (acrylic warhead scaffold) Daraxonrasib scaffold family · Scaffold | KRAS inhibitor | 100 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| High | Dolastatin 10 / auristatin core MMAE (auristatin) payload family · Scaffold | ADC payload | 100 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| High | Gabapentinoid amino-acid core Neuropathic gabapentinoid / SNRI series · Scaffold | Neuropathic · gabapentinoid | 100 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| High | KRAS G12C warhead (acrylamide pharmacophore) KRAS G12C inhibitor chemical landscape · Scaffold | KRAS inhibitor | 100 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core |
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
MedMedium exploration priority15
Upper-mid Exploration Score percentile (X-A bin)
| High exploration priority | 2D | Structure | Class | Exploration Score | Factors |
|---|---|---|---|---|---|
| Med | KRAS G12D core scaffold KRAS G12D / RAS(ON) inhibitor series · Scaffold | KRAS inhibitor | 100 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | N-benzylpiperidine pharmacophore Cognitive modulator series · Scaffold | Cognition · dementia | 100 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | PARP nicotinamide pharmacophore PARP inhibitor chemical series · Scaffold | PARP inhibitor | 100 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | BRAF hinge-binding aryl core BRAF / MEK inhibitor chemical series · Scaffold | BRAF / MEK | 99 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | Duocarmycin CPI core Duocarmycin CPI ADC payload series · Scaffold | ADC payload | 99 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | Phenylaminopyrimidine kinase core BCR-ABL TKI chemical series · Scaffold | BCR-ABL TKI | 99 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | Pyrrolopyrimidine CDK4/6 core CDK4/6 inhibitor chemical series · Scaffold | CDK4/6 inhibitor | 99 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | ALK aminopyridine pharmacophore ALK / ROS1 TKI chemical series · Scaffold | ALK / ROS1 TKI | 98 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | Camptothecin (parent alkaloid) SN-38 / irinotecan (TOP1) small-molecule series · Scaffold | TOP1 inhibitor | 98 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | Camptothecin / exatecan core Exatecan / DXd (TOP1 inhibitor) payload family · Scaffold | TOP1 inhibitor | 97 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | Enediyne warhead core Calicheamicin enediyne payload family · Scaffold | ADC payload | 96 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | GLP-1 incretin pharmacophore GLP-1 / incretin agonist series · Scaffold | GLP-1 / incretin | 96 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | PBD monomer (anthramycin lineage) PBD dimer ADC payload family · Scaffold | ADC payload | 96 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | PCSK9-binding macrocyclic peptide pharmacophore PCSK9 inhibitor chemical & modality series · Scaffold | PCSK9 / LDL-C | 96 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | 1,4-Benzodiazepine core Benzodiazepine GABA-A modulators · Scaffold | Anxiolytic · GABA | 95 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core |
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
MedMedium exploration priority23
Mid-pool Exploration Score (X-B bin)
| High exploration priority | 2D | Structure | Class | Exploration Score | Factors |
|---|---|---|---|---|---|
| Med | Bifunctional degrader scaffold (E3 recruiter) PROTAC / bifunctional degrader series · Scaffold | PROTAC / degrader | 95 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | Cleavable linker scaffold ADC linker chemical families · Scaffold | ADC linker | 95 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | Imidazopyridine pharmacophore Sleep / hypnotic series · Scaffold | Sleep · hypnotic | 95 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | Indole tryptamine pharmacophore Migraine triptan series · Scaffold | Migraine · triptan | 95 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | Morpholino-pyrimidine PI3K pharmacophore PI3K / AKT / mTOR inhibitor series · Scaffold | PI3K / AKT / mTOR | 95 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | Multi-kinase hinge core RET / MET / NTRK oncogene TKI series · Scaffold | RET / MET / NTRK TKI | 95 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | Phenethylamine pharmacophore ADHD stimulant / non-stimulant series · Scaffold | ADHD | 95 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | Pyrrolidinone carboxamide core Antiepileptic drug chemical series · Scaffold | Antiepileptic · AED | 95 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | Sphingosine-like pharmacophore MS S1P modulator series · Scaffold | MS · S1P | 95 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | BH3-mimetic scaffold BCL-2 BH3-mimetic inhibitor series · Scaffold | BCL-2 inhibitor | 94 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | C-glucoside SGLT2 pharmacophore SGLT2 inhibitor series · Scaffold | SGLT2 inhibitor | 94 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | Dihydroxyheptanoate pharmacophore Statin HMG-CoA reductase inhibitor series · Scaffold | Statin / HMG-CoA | 94 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | Piperazine aryl pharmacophore Atypical antipsychotic series · Scaffold | Antipsychotic | 94 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | Pyrrolopyrimidine JAK core JAK inhibitor chemical series · Scaffold | JAK inhibitor | 94 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | CGRP urea / amide pharmacophore CGRP gepant migraine series · Scaffold | Migraine · CGRP gepant | 93 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | Maytansine core DM1 / maytansinoid payload family · Scaffold | Maytansinoid | 93 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | MMAE (monomethyl auristatin E) MMAE (auristatin) payload family · Payload | ADC payload | 91 | Payload core · SMILES 확보 · 승인·상용 신호 · 패밀리 12종 | |
| Med | DXd (deruxtecan payload) Exatecan / DXd (TOP1 inhibitor) payload family · Payload | TOP1 inhibitor | 89 | Payload core · SMILES 확보 · 승인·상용 신호 · 패밀리 12종 | |
| Med | Taxane tetracyclic core Taxane diterpenoid series · Scaffold | Taxane / microtubule | 86 | 패밀리 core · Pharmacophore · SMILES 확보 · SAR/core | |
| Med | Dara-P1 (ADC payload) Daraxonrasib scaffold family · Payload | KRAS inhibitor | 68 | Payload core · SMILES 확보 · 패밀리 15종 · 파생 2건 | |
| Med | Dara-P2 (ADC payload) Daraxonrasib scaffold family · Payload | KRAS inhibitor | 68 | Payload core · SMILES 확보 · 패밀리 15종 · 파생 2건 | |
| Med | Dara-P3 (next-gen payload) Daraxonrasib scaffold family · Payload | KRAS inhibitor | 65 | Payload core · SMILES 확보 · 패밀리 15종 · 고관심 계열 | |
| Med | Duocarmycin SA Duocarmycin CPI ADC payload series · Payload | ADC payload | 64 | Payload core · SMILES 확보 · 파생 2건 · 고관심 계열 |
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
Payload core · SMILES 확보 · 승인·상용 신호 · 패밀리 12종
Payload core · SMILES 확보 · 승인·상용 신호 · 패밀리 12종
패밀리 core · Pharmacophore · SMILES 확보 · SAR/core
Payload core · SMILES 확보 · 패밀리 15종 · 파생 2건
Payload core · SMILES 확보 · 패밀리 15종 · 파생 2건
Payload core · SMILES 확보 · 패밀리 15종 · 고관심 계열
Payload core · SMILES 확보 · 파생 2건 · 고관심 계열
LowLow exploration priority29
Lower Exploration Score — still listed for inspection (X-C bin)
| High exploration priority | 2D | Structure | Class | Exploration Score | Factors |
|---|---|---|---|---|---|
| Low | MMAF (monomethyl auristatin F) MMAE (auristatin) payload family · Payload | ADC payload | 64 | Payload core · SMILES 확보 · 패밀리 12종 · 고관심 계열 | |
| Low | N-acetyl-γ-calicheamicin Calicheamicin enediyne payload family · Payload | ADC payload | 64 | Payload core · SMILES 확보 · 파생 2건 · 고관심 계열 | |
| Low | SG3199 (PBD dimer warhead) PBD dimer ADC payload family · Payload | ADC payload | 64 | Payload core · SMILES 확보 · 파생 2건 · 고관심 계열 | |
| Low | Auristatin E (parent) MMAE (auristatin) payload family · Scaffold | ADC payload | 63 | Pharmacophore · SMILES 확보 · 패밀리 12종 · 고관심 계열 | |
| Low | DM1 (mertansine) DM1 / maytansinoid payload family · Payload | Maytansinoid | 63 | Payload core · SMILES 확보 · 패밀리 9종 · 파생 3건 | |
| Low | Calicheamicin γ¹ Calicheamicin enediyne payload family · Payload | ADC payload | 61 | Payload core · SMILES 확보 · 고관심 계열 | |
| Low | KRAS-targeted payload analog 1 KRAS G12C inhibitor chemical landscape · Payload | KRAS inhibitor | 61 | Payload core · SMILES 확보 · 패밀리 13종 · 고관심 계열 | |
| Low | Tesirine (SG3249) PBD dimer ADC payload family · Payload | ADC payload | 61 | Payload core · SMILES 확보 · 고관심 계열 | |
| Low | SMCC Daraxonrasib scaffold family · Linker | KRAS inhibitor | 60 | Linker hub · SMILES 확보 · 패밀리 15종 · 고관심 계열 | |
| Low | Sulfo-SPDB Daraxonrasib scaffold family · Linker | KRAS inhibitor | 60 | Linker hub · SMILES 확보 · 패밀리 15종 · 고관심 계열 | |
| Low | Mc-VC-PABC Daraxonrasib scaffold family · Linker | KRAS inhibitor | 58 | Linker hub · SMILES 확보 · 패밀리 15종 · 고관심 계열 | |
| Low | Seco-duocarmycin Duocarmycin CPI ADC payload series · Payload | ADC payload | 56 | Payload core · SMILES 확보 · 고관심 계열 | |
| Low | DM4 (soravtansine) DM1 / maytansinoid payload family · Payload | Maytansinoid | 55 | Payload core · SMILES 확보 · 패밀리 9종 | |
| Low | SN-38 payload (cross-family) DM1 / maytansinoid payload family · Payload | Maytansinoid | 55 | Payload core · SMILES 확보 · 패밀리 9종 | |
| Low | Val-Cit MMAE (auristatin) payload family · Linker | ADC payload | 55 | Linker hub · SMILES 확보 · 패밀리 12종 · 고관심 계열 | |
| Low | SN-38 ADC linker-payload design SN-38 / irinotecan (TOP1) small-molecule series · Payload | TOP1 inhibitor | 53 | Payload core · SMILES 확보 | |
| Low | Acyl hydrazone linker Calicheamicin enediyne payload family · Linker | ADC payload | 52 | Linker hub · SMILES 확보 · 고관심 계열 | |
| Low | Val-Ala PBD linker PBD dimer ADC payload family · Linker | ADC payload | 52 | Linker hub · SMILES 확보 · 고관심 계열 | |
| Low | Duocarmycin Val-Cit linker node Duocarmycin CPI ADC payload series · Linker | ADC payload | 50 | Linker hub · SMILES 확보 · 고관심 계열 | |
| Low | GGFG (cleavable linker) Exatecan / DXd (TOP1 inhibitor) payload family · Linker | TOP1 inhibitor | 49 | Linker hub · SMILES 확보 · 패밀리 12종 | |
| Low | CL2A (lysine-cleavable linker) Exatecan / DXd (TOP1 inhibitor) payload family · Linker | TOP1 inhibitor | 47 | Linker hub · SMILES 확보 · 패밀리 12종 | |
| Low | Mc-VC-PABC family ADC linker chemical families · Linker | ADC linker | 47 | Linker hub · SMILES 확보 · 패밀리 8종 | |
| Low | Val-Cit family ADC linker chemical families · Linker | ADC linker | 47 | Linker hub · SMILES 확보 · 패밀리 8종 | |
| Low | CL2A family ADC linker chemical families · Linker | ADC linker | 45 | Linker hub · SMILES 확보 · 패밀리 8종 | |
| Low | GGFG family ADC linker chemical families · Linker | ADC linker | 45 | Linker hub · SMILES 확보 · 패밀리 8종 | |
| Low | SMCC family ADC linker chemical families · Linker | ADC linker | 45 | Linker hub · SMILES 확보 · 패밀리 8종 | |
| Low | Sulfo-SPDB family ADC linker chemical families · Linker | ADC linker | 45 | Linker hub · SMILES 확보 · 패밀리 8종 | |
| Low | SMCC-DM1 (linker-payload) DM1 / maytansinoid payload family · Linker | Maytansinoid | 44 | Linker hub · SMILES 확보 · 패밀리 9종 | |
| Low | Hydrazone family ADC linker chemical families · Linker | ADC linker | 43 | Linker hub · SMILES 확보 · 패밀리 8종 |
Payload core · SMILES 확보 · 패밀리 12종 · 고관심 계열
Payload core · SMILES 확보 · 파생 2건 · 고관심 계열
Payload core · SMILES 확보 · 파생 2건 · 고관심 계열
Pharmacophore · SMILES 확보 · 패밀리 12종 · 고관심 계열
Payload core · SMILES 확보 · 패밀리 9종 · 파생 3건
Payload core · SMILES 확보 · 고관심 계열
Payload core · SMILES 확보 · 패밀리 13종 · 고관심 계열
Payload core · SMILES 확보 · 고관심 계열
Linker hub · SMILES 확보 · 패밀리 15종 · 고관심 계열
Linker hub · SMILES 확보 · 패밀리 15종 · 고관심 계열
Linker hub · SMILES 확보 · 패밀리 15종 · 고관심 계열
Payload core · SMILES 확보 · 고관심 계열
Payload core · SMILES 확보 · 패밀리 9종
Payload core · SMILES 확보 · 패밀리 9종
Linker hub · SMILES 확보 · 패밀리 12종 · 고관심 계열
Payload core · SMILES 확보
Linker hub · SMILES 확보 · 고관심 계열
Linker hub · SMILES 확보 · 고관심 계열
Linker hub · SMILES 확보 · 고관심 계열
Linker hub · SMILES 확보 · 패밀리 12종
Linker hub · SMILES 확보 · 패밀리 12종
Linker hub · SMILES 확보 · 패밀리 8종
Linker hub · SMILES 확보 · 패밀리 8종
Linker hub · SMILES 확보 · 패밀리 8종
Linker hub · SMILES 확보 · 패밀리 8종
Linker hub · SMILES 확보 · 패밀리 8종
Linker hub · SMILES 확보 · 패밀리 8종
Linker hub · SMILES 확보 · 패밀리 9종
Linker hub · SMILES 확보 · 패밀리 8종
Exploration score method
StructureMoa ranks are a rule-based Exploration Score. An LLM does not predict activity or efficacy. Role, SMILES, and relation signals inside each family are summed and cut into High / Medium / Low exploration priority.
Core tab
- scaffold / payload / linker role weights
- family center-compound bonus
- SMILES source (db · known · pubchem · inherited)
- relation-edge count and derived-child count
Derivative tab
- drug / derivative / adc candidates
- similarity to family center via Morgan fingerprint, radius 2, 2048 bits, Tanimoto
- approved / clinical catalog-tag bonuses
- ADC / payload tags
Explore tab
- sparse SAR, cross-scaffold pairs, expansion leaves
- weakly linked nodes and approved-tag neighborhood gaps
- relation graph + stored Morgan fingerprints
- category filters
Exploration-priority bins
- High (X-S): top ~12%
- Medium (X-A/X-B): ~12–62%
- Low (X-C): remainder (pools under 5 compounds stay Medium)
Internal exploration metric based on catalog and structural signals. Not a prediction of efficacy, safety, potency, or development success.
평가 시각: 2026. 9. 11. 오전 3:14:24 · 캐시 5분 · 전체 패밀리